The Congressional Budget Office estimated in 2024 that covering GLP-1 drugs for obesity would cost Medicare $35 billion from 2026 to 2034, against offsetting savings of only $3.4 billion
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S
With manufacturing of approved products now keeping up with demand, the prior justification for compounded GLP-1s has largely disappeared
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency
Pricing for compounded options starts around $179 per month, which is designed to make GLP-1 treatment accessible without the cost barriers that come with brand-name medications
Stomach grumbling cramps, whole body is aching, extremely tired, bad headache and a bit anxious